Abstract
Clinicians sometimes use switching strategies based on regimens such as RAL + ABC/3TC or RPV + ABC/3TC in order to resolve tolerability or safety issues associated with conventional recommended first-line strategies. Despite the low genetic barrier of these regimens, high safety and efficacy rates have been reported in retrospective studies.
Keywords:
Abacavir/lamivudine; Efficacy; Raltegravir; Rilpivirine; Safety; Switching.
MeSH terms
-
Anti-HIV Agents / adverse effects
-
Anti-HIV Agents / economics
-
Anti-HIV Agents / pharmacology*
-
Anti-HIV Agents / therapeutic use*
-
Antiretroviral Therapy, Highly Active / adverse effects
-
Antiretroviral Therapy, Highly Active / economics
-
Dideoxynucleosides / adverse effects
-
Dideoxynucleosides / pharmacology
-
Dideoxynucleosides / therapeutic use
-
Drug Combinations
-
Drug Resistance, Viral / genetics
-
Drug Substitution
-
HIV Infections / drug therapy*
-
HIV Infections / genetics
-
HIV Infections / virology
-
HIV-1 / drug effects*
-
HIV-1 / genetics
-
Humans
-
Lamivudine / adverse effects
-
Lamivudine / pharmacology
-
Lamivudine / therapeutic use
-
Raltegravir Potassium / adverse effects
-
Raltegravir Potassium / therapeutic use
-
Rilpivirine / adverse effects
-
Rilpivirine / therapeutic use
-
Treatment Outcome
-
Viral Load / drug effects
Substances
-
Anti-HIV Agents
-
Dideoxynucleosides
-
Drug Combinations
-
abacavir, lamivudine drug combination
-
Lamivudine
-
Raltegravir Potassium
-
Rilpivirine